Anti-angiogenic therapies for malignant pleural mesothelioma

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 833-844

  Ceresoli, Giovanni Luca ^a   Zucali, Paolo Andrea ^b  

^a Humanitas Gavazzeni Hospital   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Angiogenesis; Biomarkers; Malignant pleural mesothelioma; Therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CISPLATIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; LENVATINIB; PAZOPANIB; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR HOMING PEPTIDE TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LIVER TOXICITY; MALIGNANT MESOTHELIOMA; MOLECULAR BIOLOGY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PREDICTION; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOEMBOLISM; THROMBOSIS; UNINDEXED SEQUENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MESOTHELIOMA; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861047319     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.681641     Document Type: Review

References (79)

1. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603 (Pubitemid 41434638)
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90
3. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65 . (Pubitemid 29022249)
4. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72
5. Mc Aleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2009;75:326-37
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44 (Pubitemid 46606305)
7. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61 (Pubitemid 46594110)
8. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443-8 (Pubitemid 46622011)
9. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-3 (Pubitemid 351201722)
10. Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 2008;3:756-63
11. Ceresoli GL, Zucali PA, Gianoncelli L, et al. Second-line treatment for malignant pleural mesotelioma. Cancer Treat Rev 2010;36:24-32
12. Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesotelioma. Cancer Treat Rev 2011;37:543-58
13. Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005;128:3382-7 (Pubitemid 41698667)
14. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75 (Pubitemid 32266815)
15. Linder C, Linder S, Munck-Wikland E, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998;18:2063-8 (Pubitemid 28344873)
16. Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol 1999;189:72-8 (Pubitemid 29406822)
17. Ocana A, Amir E, Vera F, et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011;29:254-6
18. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):7526 .
19. Li Q, Yano S, Ogino H, et al. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesotelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007;13:5918-25 (Pubitemid 47583920)
20. Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma [abstract S06-3]. Proceedings of the X International Conference of the IMIG (International Mesothelioma Interest Group); Kyoto (Japan); 2010
21. Dowell J, Taub R, Lan C, et al. A multicenter phase II study of pemetrexed, cisplatin and bevacizumab in patients with advanced malignant mesothelioma. J Clin Oncol 2009;27(15s):abstract 7578
22. Zalcman G, Margery J, Scherpereel A, et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II-III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 2010;28(15s):abstract 7020
23. Carboplatin, bevacizumab and pemetrexed in the first-line treatment of patients with malignant pleural mesothelioma. NCT00604461. Available from: www.ClinicalTrials.gov
24. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-14
25. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005;48:291-6
26. Pavlakis N, Abraham R, Harvie R, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma (MM): interim results from two parallel non randomized phase II studies [abstract O-26]. Lung Cancer 2003;41(Suppl 2):S11
27. Baas P, Buikhuisen W, Dalesio O, et al. A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J Clin Oncol 2011;29:abstract 7006
28. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in Malignant Mesothelioma: a University of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 2001;20:abstract 1359
29. Dubey S, Janne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma. Results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010;5:1655-61
30. Irshad S, Popat R, Shah S, et al. A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18FDG-PET. J Clin Oncol 2010;28(15s):abstract 7038
31. Mutri V, Pinto C, Giaquinta S, et al. Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma patients: italian SoMe study. J Clin Oncol 2011;29:abstract 7087
32. Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
33. Katz SI, Zhou L, Chao G, et al. Sorafenib inhibits ERK1/2 and MCL-IL posphorylation lebels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther 2009;8:2406-16
34. Nowak A, Millward M, Francis R, et al. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma [abstract S13-1]. Proceedings of the X International Conference of the IMIG (International Mesothelioma Interest Group); Kyoto (Japan); 2010
35. Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC clinical trials group. J Thorac Oncol 2011;6:1950-4
36. Chow LQM, Blais N, Jonker DJ, et al. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol 2011;published online 12 October 2011; doi: 10.1007/s00280-011-1755-0.
37. Okamoto I, Shimizu T, Miyazaki M, et al. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Invest New Drugs 2010;published online 20 October 2010; doi:10.1007/s10637-010-9565-5.
38. A study to find the best dose of SU01248 when given with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors. NCT00528619 Available from: www.ClinicalTrials.gov
39. Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2011;published online 22 December 2011; doi: 10.1016/j. lungcan.2011.11.014
40. Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma. SWOG S0509. J Thorac Oncol 2011;6:1938-45
41. Pemetrexed disodium and cisplatin with or without cediranib maleate in treating patients with malignant pleural mesothelioma. NCT01064648 Available from: www.ClinicalTrials.gov
42. Ogino H, Yano S, Kakiuchi S, et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 2008;265:55-66
43. Giovannetti E, Zucali PA, Assarat YG, et al. Preclinical emergence of vandetanib as a potent antitumour agent in mesotelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011;105:1542-53
44. An efficacy and safety study with vandetanib to treat inoperable or relapsed malignant mesothelioma. NCT00597116 Available from: www. ClinicalTrials.gov
45. Pazopanib in treating patients with malignant pleural mesothelioma. NCT00459862 Available from: www.ClinicalTrials.gov
46. Axitinib in malignant mesothelioma (N08CPA). NCT01211275 Available from: www.ClinicalTrials.gov
47. Buikhuisen W, Griffioen A, Marijt K, et al. Tissue response in patients with MPM after treatment with cisplatin, pemetrexed and axitinib: first results of a feasibility study [abstract. S13-4]. Proceedings of the X International Conference of the IMIG (International Mesothelioma Interest Group); Kyoto (Japan); 2010
48. Ikuta K, Yano S, Trung VT, et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 2009;15:7229-37
49. Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17:2528-37
50. Rangel R, Sun Y, Guzman-Rojas L, et al. Impaired angiogenesis in aminopeptidase N-null mice. PNAS 2007;104:4588-93 (Pubitemid 47186269)
51. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82 (Pubitemid 34919701)
52. van Laarhoven HWM, Fiedler W, Desar IME, et al. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 2010;16:1315-23
53. Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010;28:2604-11
54. NGR015: Study in second line for patients with advanced malignant pleural mesothelioma pretreated with pemetrexed. NCT01098266 Available from: www.ClinicalTrials.gov
55. Phase II study of NGR-hTNF versus placebo as maintenance treatment in patients with advanced malignant pleural mesothelioma (NGR019). NCT01358084 Available from: www. ClinicalTrials.gov
56. Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916-23 (Pubitemid 37433592)
57. Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26:189-93 (Pubitemid 34107872)
58. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312 (Pubitemid 351717519)
59. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142-51 (Pubitemid 38056291)
60. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest 2003;112:1134-6 (Pubitemid 38056288)
61. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34
62. Langerak A, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor alpha-and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochem Biophys Acta 1996;1305:63-70 (Pubitemid 26051947)
63. Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007;62:690-5 (Pubitemid 47235011)
64. Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008;14:541-8 (Pubitemid 351226124)
65. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149-50 (Pubitemid 44796113)
66. Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-6 (Pubitemid 41297473)
67. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003;22(228S):abstract 912
68. Villano JL, Husain AN, Stadler WM, et al. A phase II trial of imatinib mesylate in patients with malignant mesothelioma (MM) ASCO Annual meeting proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S Suppl):7200
69. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95 (Pubitemid 30208155)
70. Strizzi L, Vianale G, Catalano A, et al. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001;18:1093-8
71. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85:863-8 (Pubitemid 33010554)
72. Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997;182:211-16 (Pubitemid 27287844)
73. Pathak AP, Hochfeld WE, Goodman SL, Pepper MS. Circulating and imaging markers for angiogenesis. Angiogenesis 2008;11:321-35
74. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38 .
75. de Langen AJ, Lubberink M, Boellaard R, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med 2008;49:1763-8
76. Clamp AR, Jayson GC. The role of imaging in the clinical development of antiangiogenic agents. From: cancer drug discovery and development. In: Teicher BA, Ellis LM, editors. Antiangiogenic Agents in Cancer Therapy. Humana Press; Totowa, NJ: 2008 .
77. Giesel FL, Choyke PL, Mehndiratta A, et al. Pharmacokinetic analysis of malignant pleural mesothelioma : initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Acad Radiol 2008;15:563-70 (Pubitemid 351509763)
78. Carmeliet P, Jain RK. Molecular mechanisms and clinical application of angiogenesis. Nature 2011;473:298-307
79. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603